Abstracts tagged "gout"

Abstract Number: 741 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Recurrent Gout Attacks During Hospitalization
Yuqing Zhang¹, Clara Chen², Hyon K. Choi³, Christine E. Chaisson², David J. Hunter⁴ and Tuhina Neogi⁵, ¹Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁵Clinical Epidemiology, Boston Univ Schl of Med, Boston, MA
Background/Purpose: While anecdotal evidence suggests that risk of recurrent gout attack increases during hospitalization and gout is one of the most common reasons for in-patient…
Abstract Number: 101 • 2012 ACR/ARHP Annual Meeting
Kidney Function and the Risk of Incident Gout in A Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study
Mara McAdams DeMarco¹, Anna Kottgen², Andrew Law³, Janet W. Maynard⁴, Josef Coresh¹ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Renal Division, University Hospital Freiburg, Freiburg, Germany, ³Epidemiology, Johns Hopkins, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The 1-year cumulative incidence of gout in patients with new onset end stage renal disease is 5% and rises to 15% by 5 years,…
Abstract Number: 1907 • 2012 ACR/ARHP Annual Meeting
Pharmacological Management of Gout in Italy in the Years 2005-2009: A Nationwide, Population-Based Study
Lorenzo Cavagna¹, Gianluca Trifirò², Roberto Caporali³, P. Morabito², C. Ferrajolo⁴, S. Pecchioli⁵, M. Simonetti⁵, G. Medea⁶, C. Cricelli⁷, A. Caputi², G. Mazzaglia⁵ and Carlomaurizio Montecucco⁸, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy, ³Division of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, Pavia, Italy, ⁴Department of Experimental Medicine, Pharmacology Section, Second University of Naples, Naples, Italy, ⁵Health Search, Italian College of General Practitioners, Italy, ⁶Italian college of General Practitioner, Italy, ⁷Italian college of General Practitioner, Pavia (italy), Italy, ⁸Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
Background/Purpose: Despite the increasing interest on gout, only few nationwide drug utilization studies have been conducted on this topic. The aim of this study…
Abstract Number: 742 • 2012 ACR/ARHP Annual Meeting
Utility of HLA-B5801 Genotyping and Renal Dosing of the Starting Dose of Allopurinol in Preventing Allopurinol Hypersensitivity Syndrome: A Cost-Effectiveness Analysis
Yanyan Zhu¹, Ada Man², Tuhina Neogi³ and Hyon K. Choi⁴, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy (~ 95%) for gout which affects 8.3 million US adults. However, allopurinol is associated with a…
Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 167 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Maria Manara¹, Carlo Alberto Scirè¹, Marco A. Cimmino², Marcello Govoni³, Fausto Salaffi⁴, Greta Carrara¹, Carlomaurizio Montecucco⁵, Marco Matucci-Cerinic⁶, Giovanni Minisola⁷ and Kick-off of the Italina Network for Gout (KING) Study Group⁸, ¹Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ²Rheumatology - Department of Internal Medicine - University of Genoa, Genova, Italy, ³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ⁴Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, ⁵Division of Rheumatology - University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁶Department of Biomedicine & Division of Rheumatology AOUC - University of Florence, Florence, Italy, ⁷Rheumatology Unit - San Camillo Forlanini Hospital, Rome, Italy, ⁸Italian Society for Rheumatology, SIR, Italy
Background/Purpose: the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines…
Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT
T. Bardin¹, A. So², R. Alten³, M. Bloch⁴, M. R. John⁵, G. Krammer⁵, J. M. Nebesky⁵, A. Tao⁶ and N. Schlesinger⁷, ¹Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ²Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ³Charité Univ Medicine, Berlin, Germany, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…
Abstract Number: 168 • 2012 ACR/ARHP Annual Meeting
Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction
Lamiae Grimaldi-Bensouda¹, Annick Alpérovitch², Elodie Aubrun¹, Nicolas Danchin³, Michel Rossignol⁴, Lucien Abenhaim⁵, Pascal Richette⁶ and PGRx MI Group⁷, ¹LA-SER, Paris, France, ²Inserm U708-Neuroepidemiology, La Pitié-Salpêtrière Hospital, Paris, France, ³Coronary disease unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris and Paris-Descartes University, Paris, France, ⁴LA-SER, Centre for Risk Research, Montreal, Canada, ⁵LA-SER Europe Ltd, London, United Kingdom, ⁶Lariboisière Hospital, Paris, France, ⁷Paris, France
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and the oxidative stress in the vasculature, which are known cardiovascular risk factors. However, the effects…
Abstract Number: 1912 • 2012 ACR/ARHP Annual Meeting
Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 16 Hours in Patients with Acute Gout Flares
Suman Wason¹, Thomas Lauterio¹, Steve Crockett¹ and Matthew W. Davis², ¹Clinical Development, URL Pharma, Philadelphia, PA, ²Clinical Pharmacology, URL Pharma, Philadelphia, PA
Background/Purpose: The management of patients with gout remains suboptimal, leading to increasing frequency and severity of recurrent flares that eventually lead to joint destruction and…
Abstract Number: 150 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Alan S. Hollister¹, Andreas Maetzel¹, Michael A. Becker², Robert Terkeltaub³, David Fitz-Patrick⁴, Valerie Smith⁵ and William P. Sheridan⁶, ¹Development, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Medicine, University of Chicago, Chicago, IL, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴East-West Medical Research Institute, Honolulu, HI, ⁵Pharpoint Research, Inc., Durham, NC, ⁶BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: A majority of gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid concentration (sUA) of 4…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].